Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subanesthetic Esketamine for Postoperative Mood and Pain After Modified Radical Mastectomy
ChiCTR2200057028Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in breast cancer, major depressive disorder (MDD) and postoperative pain comparing Esketamine 0.25 mg/kg IV with Normal saline placebo IV (2 arms). Primary endpoints: Patient Health Questionnaire-9 (PHQ-9) score and Visual Analogue Scale (VAS) pain score. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
breast cancermajor depressive disorder (MDD)postoperative pain
Beyond the preview
Go deeper on ChiCTR2200057028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057028.